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cisplatin in 5 patients (14 courses), mainly due to nephrotoxicity. Three 
patients developed pulmonary embolism during treatment. Overall 
median total dose for radiotherapy was 55 Gy (range 6-60), patients eli-
gible for surgery received a median total dose of 48 Gy (range 46-60). 
Percentage of normal lung volume receiving 20 Gy (V20) ranged from 
0 - 44.6%. Esophagitis >grade I was observed in 35 patients (61.4%): 
Grade II (n=22) and grade III (n=13). Two patients were not evaluable 
for radiological response. Forty-one patients had a partial response, 9 
stable disease and 5 progressive disease. Objective response rate (ORR) 
is therefore 74.5% (95% CI: 61.6 - 84.3%). Nineteen patients (15 
stage III) underwent a (radical) resection after restaging, and 7 of these 
had a complete pathological remission (cPR). All cPR patients had a 
radiological partial response. After a median follow up of 10 months, 
38 patients (66.7%) are alive. Local recurrence of NSCLC occurred in 
9 patients, 6 developed distant metastatic disease, of whom 4 had brain 
metastases.
Conclusion: Chemoradiotherapy with cisplatin/gemcitabine followed 
by cisplatin/etoposide and concurrent thoracic radiotherapy for ir-
resectable or medically inoperable NSCLC patients is relatively well 
tolerated and shows a high objective response rate.
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Background: The most satisfactory treatment for patients with locally 
advanced NSCLC is combination chemotherapy-radiotherapy (CT-RT). 
However, the optimal interval between irradiation and chemotherapy as 
well as the most effective chemotherapy protocol remains to be deﬁned.
Our aim was to conduct a multicenter phase II trial of the cisplatin-oral 
vinorelbine -radiotherapy combination after induction chemotherapy 
with cisplatin-docetaxel in patient with NSCLC. Vinorelbine is effec-
tive as the intravenous form in concomitance with RT for the treatment 
of NSCLC and oral form may reduce some disagreements provoked by 
intravenous injections: stress, infections, hemorrhage, displacement at 
the hospital and cost of CT. 
Method: Patients (pts) with histologically or cytologically conﬁrmed 
unresected stage IIIA and IIIB NSCLC previously untreated, PS ≤ 1, 
and weight loss ≤ 10 % received two cycles of induction CT cisplatin 
(75 mg/m2) and docetaxel (75mg/m2) days 1 and 22. Pts with response 
or stable disease continued with thoracic radiotherapy (2 Gy/day, 5 
days/week, total dose of 66 Gy, beginning day 57) concomitant with 2 
cycles of cisplatin (80mg/m2) (days 57 and 78) and oral vinorelbine (40 
mg/m2) (days 57, 64, 78 and 85). The interim analysis was planned on 
the ﬁrst 15 evaluated pts for response and toxicity (pts who received the 
2 sequences of treatment: induction CT and concomitant CT-RT). The 
enrollment of pts continued if more than 4 objective responses and less 
than 4 grade III-IV pulmonary or esophagus toxicity were observed. 
Results: Twenty two pts were enrolled to obtain 15 evaluated pts. 
Seven pts did not receive the concomitant CT-RT because of the fol-
lowing reasons: 3 pts presented progression disease after induction CT, 
1 died due to concomitant disease, 1 stopped treatment due to toxicity 
(pneumopathy), 2 pts were withdrawn from study because of protocol 
deviation. The characteristics of the 15 evaluated pts are: mean age 
57 (46-69), 10 males, PS 0/1 9/6 pts, stage IIIA/IIIB 5/10 pts, histol-
ogy squamous cell carcinoma/adenocarcinoma/large cell 3/8/4 pts. 
All these pts received the intended treatment. No complete response 
was observed neither after induction CT nor after concomitant CT-RT. 
Response rate to induction CT was 40% (95%CI: 15-65) (6 pts) and 
to concomitant CT-RT 80% (95%CI: 60-100) (12 pts). The overall 
response rate in ITT was 54.5% (95%CI: 33-75). One patient presented 
progression disease after concomitant CT-RT (this patient has a stable 
disease after induction CT). Median survival was not reached. Seven 
pts experienced severe toxicities after concomitant CT-RT: esophagitis 
grade III (1 pt), esophagitis grade IV (1 pt), severe neutropenia (4 pts) 
and bronchial infection (1 pt). No pulmonary toxicity and treatment 
related death occurred. 
Conclusions: The result of the interim analysis demonstrated that the 
tested combined treatment modality is feasible and well tolerated by 
the patients. This result allows us to continue patients enrollment on the 
study. The total number of patient needed is 30 evaluated pts which we 
expect to reach when 60 patients will be enrolled. Further results will 
be given at the time of the abstract presentation.
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Background and Purpose: Evidence supports concurrent chemo-
radiotherapy as an option in the treatment of locally advanced stage 
III NSCLC. We present the long term results of a prospective phase 
II study aimed to determine the response rate (RR), toxicity, time to 
progression (TTP) and survival (S) of concurrent Vinorelbine (Vrb) and 
Cisplatin (Cis) or Carboplatin ( Carbo), with radiotherapy (RT), fol-
lowed by consolidation ChT with the same drugs, for stage III NSCLC. 
In order to decrease toxicity the role of protectors like amifostine has 
been evaluated.
Methods and Materials: 58 eligible pts were included the study from 
16.11.2000 to 18.09.2003. Pts characteristics were: median age 59 
(44-71), M/F=50/8, PS 1/2=28/30, stage IIIA/IIIB=11/47, squamous 
cell cc 45, adenocc 7, adenoid chistic cc 1, large cell cc 5. Treatment 
consisted of 2 cycles of ChT with Vrb (15 mg/sqm, d 1, 8, q21) and Cis 
(80 mg/sqm, d 1, q 21) or Carbo (AUC 2.5) given concurrently with 
RT (56-60 Gy/ 28-30 fractions/5.5- 6 weeks), followed by 2-4 cycles of 
consolidation ChT with the same drugs (Vrb 25 mg/sqm d 1,8, Cis 100 
mg/sqm, or Carbo AUC 5 d1, q 21). 22 pts received Amifostine 740 
mg/sqm, d1, 8, q 21, given intravenously. At least 4 cycles of ChT have 
been completed by 64% and optimal doses of RT by 79% of pts.
Results: 58 pts were evaluable for toxicity. Severe grade 3 or 4 toxici-
ties were: neutropenia in 11(19%) pts, esophagitis in 11(19%) pts, 
